Clinical trial
The Addition of Inhaled FUROsemide to Standard of Care in COPD Exacerbation: a Randomized Double Blinded Control Trial (FUROSCOPE Trial)
NCT05769738 is registered in ClinicalTrials.gov with American University of Beirut Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Addition of Inhaled FUROsemide to Standard of Care in COPD Exacerbation: a Randomized Double Blinded Control Trial (FUROSCOPE Trial)
- Lead sponsor
- American University of Beirut Medical Center
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 31, 2023
- Completion date
- December 31, 2024
- Enrollment
- 200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease exacerbation, copd exacerbation